Vanda Pharmaceuticals Inc (NASDAQ:VNDA)
| 6.58 Data as of May 17 |  +1.08 / +19.64%Today’s Change | 2.92 Today|||52-Week Range 7.23 | +77.84% Year-to-Date |
Latest VNDA News | Press Releases
No recent news for Vanda Pharmaceuticals Inc.
Today’s Trading
| Previous close | 5.50 |
| Today’s open | 6.18 |
| Day’s range | 6.00 - 7.23 |
| Volume | 3,379,397 |
| Average volume (3 months) | 311,321 |
| Market cap | $186.5M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -180.00% |
| Earnings growth (this year) | -1.02% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | +4.66% |
| P/E ratio | NM |
| Price/Sales | 3.19 |
| Price/Book | 18.76 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AMPEAmpio Pharmaceutical... | +0.03 | +0.60% |
| SUPNSupernus Pharmaceuti... | +0.16 | +2.74% |
| ACSTAcasti Pharma Inc | 0.00 | 0.00% |
| DRTXDurata Therapeutics ... | -0.01 | -0.14% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.22 |
| Annual revenue (last year) | $32.7M |
| Annual profit (last year) | -$27.7M |
| Net profit margin | -84.53% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Mihael Hristos Polymeropoulos, MD |
CFO, Secretary, Treasurer & Senior Vice President James Patrick Kelly, CFA, MBA |
Corporate headquarters Washington, District Of Columbia |
Forecasts
